These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17390747)

  • 21. Clinical and economic impact of epoetins in cancer care.
    Marchetti M; Barosi G
    Pharmacoeconomics; 2004; 22(16):1029-45. PubMed ID: 15524492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 23. Biosimilar epoetins.
    Macdougall IC
    Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
    [No Abstract]   [Full Text] [Related]  

  • 24. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 25. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 27. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
    Wish JB; Coyne DW
    Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin claims monitoring policy: implications for clinical practice.
    Messana T
    Nephrol Nurs J; 2006; 33(2):209-13, 222; quiz 214-5. PubMed ID: 16613415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
    Nagano N
    Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
    [No Abstract]   [Full Text] [Related]  

  • 31. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 32. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A; Edelsberg J; Kallich J; Oster G
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment and costs associated with anemic chronic kidney disease patients.
    Rasu RS; Crawford T; Manley H; Balkrishnan R
    Curr Med Res Opin; 2008 Jan; 24(1):129-37. PubMed ID: 18034919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.
    Brophy DF; Ripley EB; Holdford DA
    Expert Opin Pharmacother; 2003 Sep; 4(9):1461-9. PubMed ID: 12943475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review].
    Ranchon F; Hédoux S; Laville M; Fouque D; Decullier E; Chapuis F; Huot L
    Nephrol Ther; 2010 Apr; 6(2):97-104. PubMed ID: 20097148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythropoietin in kidney disease and type 2 diabetes.
    Locatelli F; Del Vecchio L; Casartelli D
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
    [No Abstract]   [Full Text] [Related]  

  • 38. Erythropoietin in kidney disease and type 2 diabetes.
    Thum T; Kalantar-Zadeh K; Anker SD
    N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.
    Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C
    Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.